Neural signatures of risk-taking adaptions across health, bipolar disorder, and lithium treatment

IF 10.1 1区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Molecular Psychiatry Pub Date : 2025-01-29 DOI:10.1038/s41380-025-02900-w
Jacqueline Scholl, Priyanka Panchal, Natalie Nelissen, Lauren Z. Atkinson, Nils Kolling, Kate EA Saunders, John Geddes, Matthew FS Rushworth, Anna C. Nobre, Paul J. Harrison, Catherine J. Harmer
{"title":"Neural signatures of risk-taking adaptions across health, bipolar disorder, and lithium treatment","authors":"Jacqueline Scholl, Priyanka Panchal, Natalie Nelissen, Lauren Z. Atkinson, Nils Kolling, Kate EA Saunders, John Geddes, Matthew FS Rushworth, Anna C. Nobre, Paul J. Harrison, Catherine J. Harmer","doi":"10.1038/s41380-025-02900-w","DOIUrl":null,"url":null,"abstract":"Cognitive and neural mechanisms underlying bipolar disorder (BD) and its treatment are still poorly understood. Here we examined the role of adaptations in risk-taking using a reward-guided decision-making task. We recruited volunteers with high (n = 40) scores on the Mood Disorder Questionnaire, MDQ, suspected of high risk for bipolar disorder and those with low-risk scores (n = 37). We also recruited patients diagnosed with BD who were assigned (randomized, double-blind) to six weeks of lithium (n = 19) or placebo (n = 16) after a two-week baseline period (n = 22 for FMRI). Participants completed mood ratings daily over 50 (MDQ study) or 42 (BD study) days, as well as a risky decision-making task and functional magnetic resonance imaging. The task measured adaptation of risk taking to past outcomes (increased risk aversion after a previous win vs. loss, ‘outcome history’). While the low MDQ group was risk averse after a win, this was less evident in the high MDQ group and least so in the patients with BD. During fMRI, ‘outcome history’ was linked to medial frontal pole activation at the time of the decision and this activation was reduced in the high risk MDQ vs. the low risk MDQ group. While lithium did not reverse the pattern of BD in the task, nor changed clinical symptoms of mania or depression, it changed reward processing in the dorsolateral prefrontal cortex. Participants’ modulation of risk-taking in response to reward outcomes was reduced as a function of risk for BD and diagnosed BD. These results provide a model for how reward may prime escalation of risk-related behaviours in bipolar disorder and how mood stabilising treatments may work.","PeriodicalId":19008,"journal":{"name":"Molecular Psychiatry","volume":"30 7","pages":"2955-2965"},"PeriodicalIF":10.1000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41380-025-02900-w.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41380-025-02900-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cognitive and neural mechanisms underlying bipolar disorder (BD) and its treatment are still poorly understood. Here we examined the role of adaptations in risk-taking using a reward-guided decision-making task. We recruited volunteers with high (n = 40) scores on the Mood Disorder Questionnaire, MDQ, suspected of high risk for bipolar disorder and those with low-risk scores (n = 37). We also recruited patients diagnosed with BD who were assigned (randomized, double-blind) to six weeks of lithium (n = 19) or placebo (n = 16) after a two-week baseline period (n = 22 for FMRI). Participants completed mood ratings daily over 50 (MDQ study) or 42 (BD study) days, as well as a risky decision-making task and functional magnetic resonance imaging. The task measured adaptation of risk taking to past outcomes (increased risk aversion after a previous win vs. loss, ‘outcome history’). While the low MDQ group was risk averse after a win, this was less evident in the high MDQ group and least so in the patients with BD. During fMRI, ‘outcome history’ was linked to medial frontal pole activation at the time of the decision and this activation was reduced in the high risk MDQ vs. the low risk MDQ group. While lithium did not reverse the pattern of BD in the task, nor changed clinical symptoms of mania or depression, it changed reward processing in the dorsolateral prefrontal cortex. Participants’ modulation of risk-taking in response to reward outcomes was reduced as a function of risk for BD and diagnosed BD. These results provide a model for how reward may prime escalation of risk-related behaviours in bipolar disorder and how mood stabilising treatments may work.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
跨越健康、双相情感障碍和锂治疗的冒险适应的神经特征
双相情感障碍(BD)及其治疗的认知和神经机制仍然知之甚少。在这里,我们使用奖励导向的决策任务来研究适应在冒险中的作用。我们招募了在心境障碍问卷(MDQ)中得分高(n = 40)、疑似双相情感障碍高风险的志愿者和得分低(n = 37)的志愿者。我们还招募了诊断为双相障碍的患者,他们在两周的基线期(FMRI为22例)后(随机、双盲)被分配到6周的锂(n = 19)或安慰剂(n = 16)。参与者每天完成50天(MDQ研究)或42天(BD研究)的情绪评分,以及一项有风险的决策任务和功能性磁共振成像。这项任务测量了风险承担对过去结果的适应性(在之前的胜利和失败后增加的风险厌恶,“结果历史”)。虽然低MDQ组在获胜后会规避风险,但这在高MDQ组中不那么明显,在双相障碍患者中也不明显。在fMRI中,“结果史”与决策时的内侧额极激活有关,而高风险MDQ组与低风险MDQ组相比,这种激活减少了。虽然锂没有逆转任务中的双相障碍模式,也没有改变躁狂症或抑郁症的临床症状,但它改变了背外侧前额皮质的奖励加工。作为双相障碍和诊断双相障碍风险的函数,参与者对奖励结果的风险调节降低。这些结果为奖励如何引发双相障碍风险相关行为的升级以及情绪稳定治疗如何起作用提供了一个模型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Molecular Psychiatry
Molecular Psychiatry 医学-精神病学
CiteScore
20.50
自引率
4.50%
发文量
459
审稿时长
4-8 weeks
期刊介绍: Molecular Psychiatry focuses on publishing research that aims to uncover the biological mechanisms behind psychiatric disorders and their treatment. The journal emphasizes studies that bridge pre-clinical and clinical research, covering cellular, molecular, integrative, clinical, imaging, and psychopharmacology levels.
期刊最新文献
IL-15 receptor alpha deficiency triggers depressive-like behaviors via enhanced microglial synapse pruning Cell-type-specific genetic architecture reveals neuronal and immune contributions to neuropsychiatric disorders Shared and disorder-specific prenatal and perinatal risk factors for neurodevelopmental disorders: a nationwide cohort study Genetic overlap and shared risk loci between autism spectrum disorder and cardiometabolic traits. Single-cell transcriptomics of human brain disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1